Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 39, 2012, Pages 15888-15893

  Cai, Weijing ^a   Ramdas, Maya ^a   Zhu, Li ^a   Chen, Xue ^a   Striker, Gary E ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Glycotoxins; Obesity

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR 1; INSULIN RECEPTOR; PROTEIN KINASE B; SIRTUIN 1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACETYLATION; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; HOST RESISTANCE; INSULIN RESISTANCE; MACROPHAGE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOCYTES; ADMINISTRATION, ORAL; ANIMALS; DEOXYGLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INSULIN RECEPTOR SUBSTRATE PROTEINS; MACROPHAGES; METABOLIC SYNDROME X; MICE; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, IMMUNOLOGIC; SIRTUIN 1;

MUS;

EID: 84866839740     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205847109     Document Type: Article

References (45)

1. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448-1454. (Pubitemid 40396812)
2. Knip M, et al. (2005) Environmental triggers and determinants of type 1 diabetes. Diabetes 54(Suppl 2):S125-S136. (Pubitemid 43348458)
3. Wentworth JM, Fourlanos S, Harrison LC (2009) Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nat Rev Endocrinol 5:483-489.
4. van Boekel MA (2006) Formation of flavour compounds in the Maillard reaction. Biotechnol Adv 24:230-233.
5. Cai W, et al. (2002) Oxidative stress-inducing carbonyl compounds from common foods: Novel mediators of cellular dysfunction. Mol Med 8:337-346. (Pubitemid 35346213)
6. Koschinsky T, et al. (1997) Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94: 6474-6479. (Pubitemid 27270709)
7. Birlouez-Aragon I, et al. (2010) A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 91:1220-1226.
8. Vlassara H, Striker GE (2011) AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol 7:526-539.
9. Zhao Z, et al. (2009) Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 150:2569-2576.
10. Coughlan MT, et al. (2011) Advanced glycation end products are direct modulators of β-cell function. Diabetes 60:2523-2532.
11. Rabbani N, Thornalley PJ (2011) Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 22:309-317.
12. Cai W, He JC, Zhu L, Lu C, Vlassara H (2006) Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 103:13801-13806. (Pubitemid 44413988)
13. Lu C, et al. (2004) Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 101:11767-11772. (Pubitemid 39099304)
14. Torreggiani M, et al. (2009) Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol 175:1722-1732.
15. Guarente L, Franklin H (2011) Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med 364:2235-2244.
16. Liang F, Kume S, Koya D (2009) SIRT1 and insulin resistance. Nat Rev Endocrinol 5: 367-373.
17. Yoshizaki T, et al. (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29:1363-1374.
18. Uribarri J, et al. (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 34:1610-1616.
19. He CJ, Koschinsky T, Buenting C, Vlassara H (2001) Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor- 1 and elevated serum AGE. Mol Med 7:159-168. (Pubitemid 33701987)
20. Vlassara H, et al. (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94:4483-4491.
21. de Kreutzenberg SV, et al. (2010) Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: Potential biochemical mechanisms. Diabetes 59:1006-1015.
22. Cai W, et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173:327-336.
23. Vlassara H, et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99:15596-15601. (Pubitemid 35403978)
24. Thornalley PJ (2008) Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - Role inageinganddisease. DrugMetabolDrugInteract 23:125-150.
25. Liu BF, et al. (2003) Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int 63:947-957.
26. Wu L, Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809-814. (Pubitemid 34252881)
27. Cai W, et al. (2010) AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: Implications for vascular disease. Am J Physiol Cell Physiol 298:C624-C634.
28. Cai W, et al. (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: Association with increased AGER1 expression. Am J Pathol 170: 1893-1902. (Pubitemid 47339263)
29. Kilhovd BK, et al. (2003) Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52:163-167. (Pubitemid 36388837)
30. Uribarri J, et al. (2007) Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62:427-433. (Pubitemid 47065712)
31. Gillum MP, et al. (2011) SirT1 regulates adipose tissue inflammation. Diabetes 60: 3235-3245.
32. Fu MX, et al. (1996) The advanced glycation end product, Nepsilon-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986.
33. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H (1993) Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438. (Pubitemid 23207227)
34. Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW (2005) Chemical modification of proteins during peroxidation of phospholipids. J Lipid Res 46: 1440-1449. (Pubitemid 43109808)
35. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH (2008) Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 105:9793-9798. (Pubitemid 352031379)
36. Picard F, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-776. (Pubitemid 38833129)
37. Purushotham A, et al. (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9:327-338.
38. Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219-246.
39. Imai S, The NAD (2009) The NAD World: A new systemic regulatory network for metabolism and aging - Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys 53:65-74.
40. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 240:1546-1548.
41. Takahashi HK, et al. (2009) Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 330:89-98.
42. Bucala R, et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445. (Pubitemid 24297930)
43. Kamei N, et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602-26614. (Pubitemid 44401869)
44. Pramfalk C, et al. (2004) Insulin receptor activation and down-regulation by cationic lipid transfection reagents. BMC Cell Biol 5:7.
45. Taha MF, Hedayati V (2010) Isolation, identification and multipotential differentiation of mouse adipose tissue-derived stem cells. Tissue Cell 42:211-216.